Goodrx Holdings, Inc. Stock Price, News & Analysis

GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading digital healthcare platform, will present at the Cowen 43rd Annual Health Care Conference in Boston, MA, on Tuesday, March 7, 2023, at 6:50 a.m. Pacific Time (9:50 a.m. Eastern Time). A live webcast of the presentation can be accessed through the Company’s investor relations website at https://investors.goodrx.com/, with an archived recording to be available for 30 days afterward. GoodRx has been committed to making healthcare affordable, saving consumers over $45 billion since 2011, and remains one of the most downloaded medical apps in the past decade.

GoodRx Holdings Inc. (NASDAQ: GDRX) will report its fourth quarter and full year 2022 financial results on February 28, 2023, after U.S. markets close. A conference call is scheduled for 2:00 p.m. PT (5:00 p.m. ET) to discuss these results and provide insights into the company’s future outlook. Investors can pre-register for the call and access a live webcast through GoodRx's investor relations website. Since 2011, GoodRx has saved consumers over $45 billion, offering affordable medication prices and telehealth services.

GoodRx Holdings, Inc. (Nasdaq: GDRX), a top digital healthcare platform, is set to present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 11, 2023, at 3:45 p.m. PT. A live webcast of this presentation will be available on the Company's Investor Relations website and will be archived for 30 days. GoodRx has saved consumers over $45 billion since its inception in 2011, providing affordable healthcare solutions to Americans.

GoodRx Holdings, Inc. (GDRX) has reported its third-quarter 2022 financial results, achieving total revenue of $187.3 million, which surpassed previous guidance despite a 4% year-over-year decline. The net loss was $41.7 million, reflecting a challenging environment, particularly from the grocer issue affecting prescription transactions revenue, which decreased 16% to $131.2 million. However, subscription revenue grew by 63% to $26.5 million. Adjusted EBITDA was reported at $52.0 million, a decrease from the prior year, with management anticipating fourth-quarter revenue guidance of $175-$180 million, factoring continued challenges.

GoodRx (NASDAQ: GDRX) released a report indicating that expanding pharmacist prescribing authority significantly enhances access to critical medications, especially for PrEP (HIV prevention pill). The report highlights an increase in PrEP fills by 24% after one year and 110% after two years in states that allow pharmacists to prescribe. Over 37 million Americans reside in under-resourced areas where pharmacist authority could enhance healthcare access. GoodRx emphasizes that improved access leads to better medication adherence, benefiting both patients and healthcare providers.

GoodRx Holdings, Inc. (Nasdaq: GDRX), a digital healthcare platform, will present at two upcoming investor conferences. The first is the Credit Suisse 31st Annual Healthcare Conference on November 10 in Rancho Palos Verdes, CA, at 9:50 a.m. Pacific Time. The second is the Wells Fargo 6th Annual TMT Summit on December 1 in Las Vegas, NV, at 8:40 a.m. Pacific Time. Live webcasts and archived recordings will be available on the Company's Investor Relations website. GoodRx has saved consumers over $40 billion since 2011 and is among the most downloaded medical apps in the past decade.

GoodRx has launched Provider Mode, a dedicated platform for healthcare providers aimed at reducing administrative workload while facilitating patient access to medications. Since June 2021, over 850,000 prescribers have utilized GoodRx for medication pricing and discounts. With a 90% net promoter score among providers, the tool offers features like cost comparison, a dashboard for easy access to resources, and savings programs. Additionally, partnerships with companies like Biogen enhance its offerings to streamline processes for specialty therapies.

GoodRx (NASDAQ: GDRX) has launched a new feature called Provider Mode, designed to streamline the enrollment process for healthcare providers (HCPs) prescribing VUMERITY^® (diroximel fumarate) for relapsing multiple sclerosis. This digital form helps reduce paperwork and errors, significantly speeding up patient treatment initiation. Since its rollout, Provider Mode has achieved a 90% opt-in rate from providers, with Biogen (NASDAQ: BIIB) being the first pharmaceutical partner to use this system. This collaboration aims to enhance patient care by simplifying the therapy start process.

GoodRx Holdings Inc. (GDRX) will release its Q3 2022 financial results on November 8, 2022, after U.S. market close. A conference call and webcast are scheduled for the same day at 2:00 PM PT (5:00 PM ET) to discuss these results and provide business insights. GoodRx, a digital healthcare platform, has saved consumers over $40 billion since its launch in 2011. Investors can access the live call and archived materials on the Company’s investor relations website.